QLT Prostate Cancer Treatment Wins FDA OK  TORONTO (Reuters) - QLT Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=QLT.TO target=/stocks/quickinfo/fullquote"&gt;QLT.TO&lt;/A&gt; &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=QLTI.O target=/stocks/quickinfo/fullquote"&gt;QLTI.O&lt;/A&gt; said on  Wednesday it won U.S. regulatory approval for the six-month  formulation of its prostate cancer treatment, Eligard.